Live Breaking News & Updates on Nurix Therapeutic

Stay updated with breaking news from Nurix therapeutic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although. ....

How-well-is-nurix-therapeutics , Nurix-therapeutics , Nurix-therapeutic , Free-cash-flow ,

Reviewing Abeona Therapeutics (NASDAQ:ABEO) and Nurix Therapeutics (NASDAQ:NRIX)

Abeona Therapeutics (NASDAQ:ABEO – Get Rating) and Nurix Therapeutics (NASDAQ:NRIX – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, institutional ownership and valuation. Analyst Ratings This is a summary of current ratings […] ....

Texas , United-states , California , San-francisco , Dallas , Brammer-bio , Abeona-therapeutics-inc , Eb-research-partnership , Nurix-inc , Gilead-sciences-inc , Plasmatech-biopharmaceuticals-inc , Nurix-therapeutics-inc

Financial Comparison: Akebia Therapeutics (NASDAQ:AKBA) versus Nurix Therapeutics (NASDAQ:NRIX)

Akebia Therapeutics (NASDAQ:AKBA – Get Rating) and Nurix Therapeutics (NASDAQ:NRIX – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk. Volatility and Risk Akebia Therapeutics has a beta of […] ....

Australia , Japan , United-states , Massachusetts , China , California , Cambridge , Cambridgeshire , United-kingdom , Canada , Russia , San-francisco

$9.59 Million in Sales Expected for Nurix Therapeutics, Inc. (NASDAQ:NRIX) This Quarter

Brokerages expect Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Rating) to report sales of $9.59 million for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Nurix Therapeutics’ earnings, with estimates ranging from $8.00 million to $11.54 million. Nurix Therapeutics posted sales of $7.09 million during the same quarter last year, which indicates […] ....

Thomson-reuter , Robertw-baird , Zacks-investment-research , Blackrock-inc , Nasdaq , Pte-ltd , Needham-company , Ep-wealth-advisors , Wells-fargo-company , Nurix-therapeutics-inc , Nurix-therapeutics , Get-rating